IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis

Table 3 Predictive value of immunoglobulin G1 log₁₀[FA2/(FA2G2 + FA2G2)] as a response biomarker^a

Test		Result	NR	GR + MR	Sensitivity (nonresponse) (95% CI)	Specificity (response) (95% CI)	OR (95% CI)
All patients	FA2/(FA2G2 + FA2G2)-IgG1	Positive	14	12	70% (46–88)	69% (52–83)	5.3 (1.6–17.0)
All patients	FA2/(FA2G2 + FA2G2)-IgG1	Negative	6	27	70% (46–88)	69% (52–83)	5.3 (1.6–17.0)
ACPA+ and/or RF+	FA2/(FA2G2 + FA2G2)-IgG1	Positive	11	6	73% (45–92)	79% (60–92)	10.5 (2.5–45)
ACPA+ and/or RF+	FA2/(FA2G2 + FA2G2)-IgG1	Negative	4	23	73% (45–92)	79% (60–92)	10.5 (2.5–45)

Abbreviations: ACPA Anticyclic citrullinated peptide antibody, FA2 Main agalactosylated, FA2G1 Main monogalactosylated Fc glycan, FA2G2 Main digalactosylated Fc, GR Good response, IgG1 Immunoglobulin G1, MR Moderate response, NR No response, RF Rheumatoid factor
^aCutoff −0.045

ISSN: 1478-6362